 |
|
Topical Corticosteroids for Mycosis Fungoides
Experience in 79 Patients
Herschel S. Zackheim, MD;
Mohammed Kashani-Sabet, MD;
Smita Amin, MD
Arch Dermatol. 1998;134:949-954.
Objective To determine the effectiveness of topical corticosteroids in the management of mycosis fungoides.
Design Prospective study.
Setting Academic referral center, Veterans Affairs Medical Center, and private practice.
Patients Seventy-nine patients with patch or plaque stage of mycosis fungoides. Fifty-one were stage T1 (less than 10% of skin involved) and 28 were stage T2 (10% or more of skin involved). Seventy-five had patch-stage and 4 had plaque-stage disease as determined by histological examination.
Intervention Patients were treated with topical class I to III corticosteroids. Of the stage T1 patients, all used class I corticosteroids, and 4 (8%) also used class II or III corticosteroids. Of the stage T2 patients, 19 (68%) used class I and 12 (43%) used class II or III compounds. Some patients used more than 1 class of corticosteroid. Applications were almost always twice daily. Three stage T1 and 2 stage T2 patients used plastic film occlusion. Baseline and monthly morning serum cortisol levels were obtained during treatment.
Main Outcome Measures Response to treatment and side effects.
Results The median follow-up period was 9 months. Thirty-two (63%) of stage T1 patients achieved complete remission and 16 (31%) achieved partial remission, for a total response rate of 48 (94%). The comparable figures for stage T2 patients were 7 (25%), 16 (57%), and 23 (82%), respectively. Responses were determined by clinical examination. Thirty-nine patients achieved clinical clearing. In 7 of these, posttreatment biopsy speciments were obtained, and all showed histological clearing. Reversible depression of serum cortisol levels occurred in 10 (13%). Minor skin irritation occurred in 2 patients and localized, reversible skin atrophy in 1.
Conclusion Topical corticosteroids, especially class I compounds, are an effective treatment for patch-stage mycosis fungoides.
From the Cutaneous Oncology Division, Department of Dermatology, University of California, San Francisco (Drs Zackheim, Kashani-Sabet, and Amin), and the Veterans Affairs Medical Center, San Francisco (Dr Zackheim). Dr Amin is now with the Division of Dermatology, The Toronto Hospital–Western Division, University of Toronto, Toronto, Ontario.
RELATED ARTICLE
A Challenging Question Regarding the Use of Topical Corticosteroids for Mycosis Fungoides
Donald Rosenthal
Arch Dermatol. 1998;134(8):1033-1034.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Olsen et al.
Blood 2007;110:1713-1722.
ABSTRACT
| FULL TEXT
Primary Cutaneous T-Cell Lymphomas
Rosen and Querfeld
ASH Education Book 2006;2006:323-330.
ABSTRACT
| FULL TEXT
Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids: A Prospective Study
de Quatrebarbes et al.
Arch Dermatol 2005;141:1117-1120.
ABSTRACT
| FULL TEXT
Phase 1/2 Pilot Study of Methotrexate-Laurocapram Topical Gel for the Treatment of Patients With Early-Stage Mycosis Fungoides
Demierre et al.
Arch Dermatol 2003;139:624-628.
ABSTRACT
| FULL TEXT
Topical Nitrogen Mustard in the Management of Mycosis Fungoides: Update of the Stanford Experience
Kim et al.
Arch Dermatol 2003;139:165-173.
ABSTRACT
| FULL TEXT
Lymphoma of the Skin
Connors et al.
ASH Education Book 2002;2002:263-282.
ABSTRACT
| FULL TEXT
Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Duvic et al.
Arch Dermatol 2001;137:581-593.
ABSTRACT
| FULL TEXT
An Update on Treating Cutaneous T-Cell Lymphoma
Journal Watch Dermatology 1999;1999:10-10.
FULL TEXT
A Challenging Question Regarding the Use of Topical Corticosteroids for Mycosis Fungoides
Rosenthal
Arch Dermatol 1998;134:1033-1034.
FULL TEXT
|
